Acrivon Therapeutics, Inc. filed a Current Report on Form 8-K on November 6, 2026, disclosing that it had entered into and closed an asset purchase agreement with Aqilion AB to acquire oral JAK1 inhibitor and PKCθ inhibitor preclinical programs for the potential treatment of inflammatory or autoimmune diseases.

Key Highlights

  • Asset acquisition closed: Acrivon acquired Aqilion AB's programs for oral JAK1 inhibitors, including ACR-525 (formerly known as AQ280), and a PKCθ inhibitor preclinical program.
  • Target disease areas: The acquired programs are directed at the potential treatment of inflammatory or autoimmune diseases, according to the filing.
  • No milestone or royalty obligations: The company disclosed that "the Company has no obligation to make additional payments, including milestone or royalty payments, in respect of the Transaction."
  • Cash consideration: The filing states the company paid cash as consideration, but the specific amount was not disclosed in the filing text.
  • Seller identity: Aqilion AB is described as an unlisted Swedish public limited company.
  • Emerging growth company: Acrivon Therapeutics is designated as an emerging growth company under applicable securities rules, as indicated on the filing's cover page.

Acrivon Expands Immunology Pipeline Through Aqilion Asset Purchase

Acrivon Therapeutics, Inc. (NASDAQ:ACRV), a Delaware corporation headquartered in Watertown, Massachusetts, reported that it executed and consummated an asset purchase agreement with Aqilion AB, an unlisted Swedish public limited company. The acquired assets include Aqilion's programs for the discovery, research, and development of oral JAK1 inhibitors, specifically ACR-525, formerly known as AQ280, as well as a PKCθ inhibitor preclinical program. Both programs are described in the filing as targeting inflammatory or autoimmune diseases, areas distinct from oncology, where Acrivon has previously concentrated its pipeline efforts.

According to the filing, the company paid cash consideration and has no further payment obligations of any kind, including milestone payments or royalty payments, in connection with the transaction. The exact dollar amount of the cash paid was not specified in the filing text. The company's Predictive Precision Proteomics platform, referred to as the AP3 platform, is cited in the filing's forward-looking statements section in the context of its potential applicability to immunology and inflammation, though the company cautions that pursuing that field "might require additional expertise and resource allocation."

The filing was signed by Peter Blume-Jensen, M.D., Ph.D., in his capacity as Chief Executive Officer and President of Acrivon Therapeutics. The company attached a press release dated November 6, 2026 as Exhibit 99.1 to this report. The filing includes forward-looking statements subject to the company's cautionary language and risks described more fully in its reports filed with the Securities and Exchange Commission, including risks related to the ability to successfully integrate and advance ACR-525 and the PKCθ inhibitor program, regulatory requirements, and the possibility that preclinical findings may not predict results in subsequent clinical trials.

What Was Disclosed

Acrivon Therapeutics disclosed the execution and closing of an asset purchase agreement with Aqilion AB covering oral JAK1 inhibitor and PKCθ inhibitor preclinical programs. The company paid cash consideration with no additional milestone or royalty obligations, according to the filing.